New Advances in the Diagnosis and Management of NASH (Regionals)

Format: Webinar
Credit(s): 1.00 (60 min)
Webinar Date(s):
November 2, 2022 - 7:00 - 8:00 PM ET
Credit Type(s):
  • Physicians – AMA PRA Category 1 Credit(s) ™
  • Physicians/ABIM MOC – ABIM MOC Point(s)

PROGRAM OVERVIEW

Non-alcoholic steatohepatitis (NASH), an advanced form of non-alcoholic fatty liver disease (NAFLD), is a severe liver disorder with a rapidly progressive course that can lead to liver fibrosis, cirrhosis, and hepatocellular carcinoma. In order to prevent irreversible liver damage, patients with NASH should receive immediate multidisciplinary care. However, distinguishing NASH from other liver disorders and identifying high-risk patients remains challenging. Additionally, once diagnosed, there is a dearth of effective, FDA approved treatment options for NASH, with lifestyle management and supportive care remaining the primary treatment modalities. In recent years, several novel agents have emerged as potential treatment options, backed by promising clinical safety and efficacy data.

This activity, New Advances in the Diagnosis and Management of NASH, will provide gastroenterologists and hepatologists with the latest information on how to screen for, diagnose, and risk stratify NASH and how to develop patient-personalized multidisciplinary treatment plans. Clinicians will also learn about novel agents in development for NASH, the clinical trial data supporting their use, and how best to integrate these agents into clinical practice as they become available.

PROVIDER

Jointly provided by the Potomac Center for Medical Education and Rockpointe

Supported by an educational grant from Novo Nordisk.

RELATED COURSES

Advances in Cancer Screening and Detection: What PCPs Need to Know

Learn More

Optimizing LDL-C: Individualizing Treatment Using Statins and Nonstatin Therapy

Learn More

Cardiovascular Risk Reduction in T2DM: Applying Trial Data in Cardiology Practice

Learn More
This entry was posted in . Bookmark the permalink.

Follow Us :

Follow Us :

© 2021 Rockpointe Corporation

Privacy Policy

© 2021 Rockpointe Corporation

Privacy Policy